Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors

被引:5
|
作者
Wong, Ka Kit [1 ]
Frey, Kirk A. [1 ]
Niedbala, Jeremy [1 ]
Kaza, Ravi K. [1 ]
Worden, Francis P. [2 ]
Fitzpatrick, Kellen J. [1 ]
Dewaraja, Yuni K. [1 ]
机构
[1] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Endocrine Oncol, Ann Arbor, MI 48109 USA
关键词
Ga-68-DOTATATE; Lu-177-DOTATATE; neuroendocrine tumor; PET/CT; peptide receptor radionuclide therapy; SPECT/CT; SUV; theranostics; RECEPTOR RADIONUCLIDE THERAPY; SST1-SST5; DOSIMETRY; SUBTYPES; PRRT;
D O I
10.1097/MNM.0000000000001592
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy Ga-68-DOTATATE PET to post-therapy Lu-177-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT). Methods PET/CT at similar to 60 min postinjection of Ga-68 DOTATATE and research Lu-177-SPECT/CT imaging similar to at 4h (SPECT1) and similar to 24h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV)(mean) and SUVpeak for tumor, and SUVmean for non-tumoral liver (nliver), spleen and kidney. Results There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R-2 =0.19. 0.21, 0.29; PET versus SPECT2 R-2 =0.06, 0.16, 0.33 for TNRnliver,TNRspleen, TNRkidney, respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points (P<0.001). Using SUVmean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNRnliver =3.5 [CI: 3.0-3.9], TNRspleen =1.3 [CI. 1.2-1.5], TNRkidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNRnliver = 1.0 [CI: 8.2-11.7], TNRspleen = 2.9 [CI: 2.5-3.4]. TNRkidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNRnliver = 1 6.9 [CI: 1 4-1 9.9], TNRspleen =3.6 [CI: 3-4.2], TNRkidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality. Conclusions Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on Lu-177 SPECT compared with Ga-68 PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs. (C) 2022 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:892 / 900
页数:9
相关论文
共 50 条
  • [1] Comparison of 68Ga-DOTATATE and 177Lu-DOTATATE kinetics in neuroendocrine tumors
    Ilan, E.
    Lubberink, M.
    Sandstrom, M.
    Jahn, U.
    Velikyan, I.
    Andersson, C.
    Fross-Baron, K.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S276 - S277
  • [2] Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
    Zahed, Hanan
    Beauregard, Jean-Mathieu
    Abikhzer, Gad
    Rush, Christopher
    Probst, Stephan
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (01) : E12 - E15
  • [3] 177Lu-DOTATATE (Lutathera) Therapy in 68Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor
    Ventura, David
    Roll, Wolfgang
    Kasper, Hans-Udo
    Rahbar, Kambiz
    Stegger, Lars
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : E585 - E587
  • [4] Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
    Ortega, Claudia
    Wong, Rebecca K. S.
    Schaefferkoetter, Josh
    Veit-Haibach, Patrick
    Myrehaug, Sten
    Juergens, Rosalyn
    Laidley, David
    Anconina, Reut
    Liu, Amy
    Metser, Ur
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1406 - 1414
  • [5] Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT
    Lee, Hwan
    Kipnis, Sarit T.
    Niman, Remy
    O'Brien, Sophia R.
    Eads, Jennifer R.
    Katona, Bryson W.
    Pryma, Daniel A.
    CANCERS, 2024, 16 (01)
  • [6] The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors
    Metser, Ur
    Eshet, Yael
    Ortega, Claudia
    Veit-Haibach, Patrick
    Liu, Amy
    K. S. Wong, Rebecca
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (01) : 73 - 77
  • [7] Predicting 177Lu-DOTATATE SPECT Derived Red Marrow Dosimetry from Pretherapy 68Ga-DOTATATE PET and Baseline Biomarkers
    Moreau, Jill
    Wang, Chang
    Wong, Ka Kit
    Blakkisrud, Johan
    Dewaraja, Yuni
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [8] The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE
    Kepenek, Ferat
    Komek, Halil
    Can, Canan
    Kaplan, Ihsan
    Altindag, Serdar
    Gundogan, Cihan
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (06) : 509 - 517
  • [9] Malignant insulinoma: 18F-DOPA and 68Ga-DOTATATE PET/CT and treatment with 177Lu-DOTATATE
    Erhamamci, S.
    Sager, S.
    Asa, S.
    Uslu, L.
    Akgun, E.
    Sonmezoglu, K.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2020, 39 (06): : 383 - 386
  • [10] 177Lu-DOTATATE Theranostics Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers
    Peterson, Avery B.
    Wang, Chang
    Wong, Ka Kit
    Frey, Kirk A.
    Muzik, Otto
    Schipper, Matthew J.
    Dewaraja, Yuni K.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) : 393 - 399